AT1 receptor antagonists: a challenge for ACE inhibitors in diabetic nephropathy

ACE inhibitors, angiotensin receptor antagonists and bradykinin.

Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers in diabetic nephropathy? ACE inhibitors.

Diabetic nephropathy is the number one cause of endstage renal disease in the United States. Blood pressure is most important in delaying the progression of renal disease in persons with diabetes and, agents that block the renin angiotensin system (RAS) should be the primary agents used to achieve blood pressure reduction. There is debate regarding which method of RAS blockade should be used as...

ACE inhibitors versus angiotensin receptor blockers in diabetic nephropathy: is there a winner?

The review by Wilmer et al. (1) and the comments from Brenner (2) reflect the dilemma facing physicians regarding the optimal approach to the blockade of the renin-angiotensin system in diabetic nephropathy. The publication of “The Effect of Angiotensin-Converting-Enzyme Inhibition in Diabetic Nephropathy” evoked a change in the standard of care for these patients (3). The agent used in this tr...

Renoprotective role of ACE inhibitors in diabetic nephropathy.

Correspondence to: Dr C E Mogensen, Medical Department M, Endocrinology and Diabetes, Aarhus Kommunehospital, University Hospital of Aarhus, DK-8000 Aarhus C, Denmark. Patients with diabetes mellitus and overt proteinuria have a poor prognosis.' Recent studies show that appreciable proteinuria is associated with a much more rapid progression of disease than is moderate albuminuria.2 Progression...

Therapeutic controversies in hypertension management: angiotensin converting enzyme (ACE) inhibitors or angiotensin receptor blockers for diabetic nephropathy? A case for ACE inhibitors.

Diabetic nephropathy is the number one cause of endstage renal disease in the United States. Blockade of the renin angiotensin system (RAS) is important in the treatment of diabetic nephropathy. With the reports of recently completed trials examining the role of angiotensin receptor blockers (ARBs) in type 2 diabetic nephropathy, the question has arisen as to which agents are best to block the ...